ICON Public (NASDAQ:ICLR) Now Covered by Leerink Partners

Leerink Partners started coverage on shares of ICON Public (NASDAQ:ICLR) in a research report sent to investors on Wednesday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $379.00 target price on the medical research company’s stock.

A number of other research firms have also commented on ICLR. The Goldman Sachs Group began coverage on ICON Public in a research report on Thursday, June 6th. They set a buy rating and a $370.00 price target on the stock. Barclays decreased their price objective on shares of ICON Public from $355.00 to $350.00 and set an overweight rating on the stock in a report on Friday, July 26th. Truist Financial reissued a buy rating and issued a $383.00 price target on shares of ICON Public in a report on Wednesday, September 11th. TD Cowen upped their price target on ICON Public from $349.00 to $373.00 and gave the company a buy rating in a research note on Friday, May 31st. Finally, StockNews.com raised shares of ICON Public from a hold rating to a buy rating in a research note on Wednesday, September 11th. One equities research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Buy and a consensus price target of $351.60.

ICON Public Stock Performance

ICLR opened at $303.07 on Wednesday. ICON Public has a 1 year low of $221.20 and a 1 year high of $347.72. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.36. The stock’s 50 day simple moving average is $317.00 and its 200-day simple moving average is $318.08. The stock has a market cap of $25.00 billion, a PE ratio of 36.87, a P/E/G ratio of 1.29 and a beta of 1.22.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.75 EPS for the quarter, topping analysts’ consensus estimates of $3.68 by $0.07. The firm had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.14 billion. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.96 earnings per share. Sell-side analysts forecast that ICON Public will post 14.54 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ICLR. CIBC Private Wealth Group LLC boosted its stake in shares of ICON Public by 0.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 695,932 shares of the medical research company’s stock worth $196,998,000 after buying an additional 6,331 shares during the last quarter. State of Tennessee Treasury Department boosted its position in ICON Public by 4.9% during the fourth quarter. State of Tennessee Treasury Department now owns 155,797 shares of the medical research company’s stock valued at $44,101,000 after purchasing an additional 7,270 shares during the last quarter. Kornitzer Capital Management Inc. KS grew its stake in ICON Public by 15.9% in the second quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company’s stock valued at $30,016,000 after purchasing an additional 13,163 shares in the last quarter. GAMMA Investing LLC increased its position in shares of ICON Public by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock worth $82,000 after purchasing an additional 87 shares during the last quarter. Finally, Riverview Trust Co bought a new stake in shares of ICON Public during the 1st quarter worth approximately $31,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.